Susanne Maxwell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susanne Maxwell has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- David Weller
Advanced Care Research Centre, Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh
3 shared publications - Bruce Guthrie
Advanced Care Research Centre, Usher Institute, University of Edinburgh, Edinburgh, UK
2 shared publications - Caroline A. . Jackson
Usher Institute, University of Edinburgh
2 shared publications - Nazir I. Lone
Usher Institute, University of Edinburgh
2 shared publications Becky Dennison
Department of Public Health and Primary Care, University of Cambridge
1 shared publication- Bobby P. Smyth
Trinity College Dublin, Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in BMC Medicine
Non-cancer multimorbidity in people diagnosed and living with and beyond cancer: a retrospective cohort study
Background: Multimorbidity is common at cancer diagnosis, and both cancer and its treatment can lead to new long-term conditions. However, evidence on the prevalence of multimorbidity, particularly mental-physical multimorbidity, at both diagnosis and five years after cancer diagnosis remains limited. This study describes the prevalence of, and factors associated with, non-cancer multimorbidity in people newly diagnosed with cancer and those living with and beyond cancer. Methods: Retrospective cohort study of people aged 18 years and older diagnosed with, or surviving five years with one of breast, prostate, colorectal or lung cancer in 2018. For 46 long-term conditions, multimorbidity (≥ 2 non-cancer conditions), mental-physical multimorbidity (≥ 1 non-cancer physical and ≥ 1 mental health condition) and condition count (0 - ≥6 non-cancer conditions) were measured in incident and survivor cohorts, and examined by age, sex, deprivation and ethnicity. Odds of multimorbidity by cancer type was calculated using logistic regression, stratified by sex and adjusted for age, deprivation and ethnicity. Results: Analysis included 33,258 people with incident cancer and 16,807 people living with and beyond cancer (PLWBC). Multimorbidity ranged from 60 to 86% at cancer diagnosis to 70–90% in PLWBC, dependent on cancer type. Less than 20% had no additional long-term conditions at diagnosis (< 5.3% in lung cancer specifically) and less than 15% in PLWBC (< 2.3% in lung cancer). Mental-physical multimorbidity affected 24–39% at diagnosis and 27–44% in PLWBC. Both types of multimorbidity were higher in those living in the most deprived areas across all age groups. Compared with colorectal cancer, people with lung cancer had higher odds of multimorbidity at both diagnosis (in women adjusted OR 2.15 95%CI 1.86–2.49; in men aOR 1.71 95%CI 1.50–1.94) and in PLWBC (in women aOR 2.11 95%CI 1.45–3.12; in men, aOR 2.20 95%CI 1.51–3.30), whereas women with breast cancer and men with prostate cancer had lower odds. Conclusions: Most people with cancer have additional long-term conditions, with the highest prevalence in lung cancer. Clear socioeconomic inequalities in multimorbidity persist into survivorship. Cancer pathways need to ensure coordinated management of non-cancer long-term conditions between primary and secondary care across the whole cancer journey, from diagnosis through treatment and into survivorship.
- 5 October 2026
- Published by Springer Nature in BMC Medicine
Open AccessNon-cancer multimorbidity in people diagnosed and living with and beyond cancer: a retrospective cohort study
Background: Multimorbidity is common at cancer diagnosis, and both cancer and its treatment can lead to new long-term conditions. However, evidence on the prevalence of multimorbidity, particularly mental-physical multimorbidity, at both diagnosis and five years after cancer diagnosis remains limited. This study describes the prevalence of, and factors associated with, non-cancer multimorbidity in people newly diagnosed with cancer and those living with and beyond cancer. Methods: Retrospective cohort study of people aged 18 years and older diagnosed with, or surviving five years with one of breast, prostate, colorectal or lung cancer in 2018. For 46 long-term conditions, multimorbidity (≥ 2 non-cancer conditions), mental-physical multimorbidity (≥ 1 non-cancer physical and ≥ 1 mental health condition) and condition count (0 - ≥6 non-cancer conditions) were measured in incident and survivor cohorts, and examined by age, sex, deprivation and ethnicity. Odds of multimorbidity by cancer type was calculated using logistic regression, stratified by sex and adjusted for age, deprivation and ethnicity. Results: Analysis included 33,258 people with incident cancer and 16,807 people living with and beyond cancer (PLWBC). Multimorbidity ranged from 60 to 86% at cancer diagnosis to 70–90% in PLWBC, dependent on cancer type. Less than 20% had no additional long-term conditions at diagnosis (< 5.3% in lung cancer specifically) and less than 15% in PLWBC (< 2.3% in lung cancer). Mental-physical multimorbidity affected 24–39% at diagnosis and 27–44% in PLWBC. Both types of multimorbidity were higher in those living in the most deprived areas across all age groups. Compared with colorectal cancer, people with lung cancer had higher odds of multimorbidity at both diagnosis (in women adjusted OR 2.15 95%CI 1.86–2.49; in men aOR 1.71 95%CI 1.50–1.94) and in PLWBC (in women aOR 2.11 95%CI 1.45–3.12; in men, aOR 2.20 95%CI 1.51–3.30), whereas women with breast cancer and men with prostate cancer had lower odds. Conclusions: Most people with cancer have additional long-term conditions, with the highest prevalence in lung cancer. Clear socioeconomic inequalities in multimorbidity persist into survivorship. Cancer pathways need to ensure coordinated management of non-cancer long-term conditions between primary and secondary care across the whole cancer journey, from diagnosis through treatment and into survivorship.
- Open Access
- 9 March 2026
- Published by Elsevier in SSRN Electronic Journal
Non-Cancer Multimorbidity in People Diagnosed and Living with and Beyond Cancer: Cross-Sectional Population-Based Study of Four Common Cancers
Background: Comorbidities can impact the whole cancer journey from diagnosis to survivorship. This study describes the prevalence of, and factors associated with non-cancer multimorbidity at diagnosis and among five-year cancer survivors. Methods: Cross-sectional study of people aged 18+ years diagnosed with, or surviving five years with one of breast, prostate, colorectal or lung cancer in 2018. For 46 long-term conditions, condition burden, multimorbidity (≥2 non-cancer conditions) and mental-physical multimorbidity (≥1 non-cancer physical and ≥1 mental health condition) were measured in incident and survivor cohorts. Odds of multimorbidity by cancer type was calculated using logistic regression, stratified by sex and adjusted for age, deprivation and ethnicity.Findings: Analysis included 33,258 people with incident cancer and 16,807 people living with and beyond cancer (PLWBC). Multimorbidity ranged from 60-86% at cancer diagnosis to 70-90% in PLWBC, dependent on cancer type. Less than 20% had no additional long-term conditions at cancer diagnosis and less than 15% in PLWBC. Age and deprivation were significant determinants of multimorbidity with a 13-28 percentage point difference in multimorbidity between the most and least deprived groups in those aged 18-59 years. Compared with colorectal cancer, people with lung cancer had higher odds of multimorbidity at both diagnosis (in women adjusted OR 2.15 95%CI 1.86-2.49; in men aOR 1.71 95%CI 1.50-1.94) and in PLWBC (in women aOR 2.11 95%CI 1.45-3.12; in men , aOR 2.20 95%CI 1.51-3.30), whereas women with breast cancer and men with prostate cancer had lower odds.Interpretation: Multimorbidity is very common in people with cancer. The burden is highest among people with lung cancer and clear socioeconomic inequalities exist. Cancer pathways need to ensure coordinated management of non-cancer long-term conditions between primary and secondary care across the whole cancer journey from diagnosis through treatment and into survivorship.
- 9 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNon-Cancer Multimorbidity in People Diagnosed and Living with and Beyond Cancer: Cross-Sectional Population-Based Study of Four Common Cancers
Background: Comorbidities can impact the whole cancer journey from diagnosis to survivorship. This study describes the prevalence of, and factors associated with non-cancer multimorbidity at diagnosis and among five-year cancer survivors. Methods: Cross-sectional study of people aged 18+ years diagnosed with, or surviving five years with one of breast, prostate, colorectal or lung cancer in 2018. For 46 long-term conditions, condition burden, multimorbidity (≥2 non-cancer conditions) and mental-physical multimorbidity (≥1 non-cancer physical and ≥1 mental health condition) were measured in incident and survivor cohorts. Odds of multimorbidity by cancer type was calculated using logistic regression, stratified by sex and adjusted for age, deprivation and ethnicity.Findings: Analysis included 33,258 people with incident cancer and 16,807 people living with and beyond cancer (PLWBC). Multimorbidity ranged from 60-86% at cancer diagnosis to 70-90% in PLWBC, dependent on cancer type. Less than 20% had no additional long-term conditions at cancer diagnosis and less than 15% in PLWBC. Age and deprivation were significant determinants of multimorbidity with a 13-28 percentage point difference in multimorbidity between the most and least deprived groups in those aged 18-59 years. Compared with colorectal cancer, people with lung cancer had higher odds of multimorbidity at both diagnosis (in women adjusted OR 2.15 95%CI 1.86-2.49; in men aOR 1.71 95%CI 1.50-1.94) and in PLWBC (in women aOR 2.11 95%CI 1.45-3.12; in men , aOR 2.20 95%CI 1.51-3.30), whereas women with breast cancer and men with prostate cancer had lower odds.Interpretation: Multimorbidity is very common in people with cancer. The burden is highest among people with lung cancer and clear socioeconomic inequalities exist. Cancer pathways need to ensure coordinated management of non-cancer long-term conditions between primary and secondary care across the whole cancer journey from diagnosis through treatment and into survivorship.
- Open Access
- 20 May 2025
- Published by Taylor & Francis in Colorectal Cancer
- Vol. 14 (1)
Stratified/risk-based screening for colorectal cancer in the UK: an overview
While colorectal cancer screening is well-established in the UK, at present, it uses a ‘one-size fits-all’ approach – that is, individual risk is not considered when determining screening regimens (except for some specific conditions such as Lynch syndrome). Stratified screening offers the prospect of directing more intensive screening toward those at higher risk – with a corresponding reduction of screening intensity among lower-risk individuals. Two key opportunities for stratifying colorectal cancer screening are (1) making better use of an individual’s quantitative fecal hemoglobin result rather than the current approach of deeming tests to be positive over an arbitrary threshold and (2) gathering information on lifestyle, family history, genetics and other factors to establish risk of colorectal cancer – and using this information to tailor screening regimens. While there is encouraging evidence from modeling studies demonstrating reduced colonoscopy requirements and increased positive prediction of colorectal cancer when incorporating risk assessments within screening, we need ‘real world’ evidence on stratified screening to establish whether it is effective, improves screening outcomes and is acceptable to the public. We also need to know the impact these changes would have on existing screening programs, and how programs might adapt their organizational and IT processes.
- 20 May 2025
- Published by Taylor & Francis in Colorectal Cancer
- Vol. 14 (1)
Open AccessStratified/risk-based screening for colorectal cancer in the UK: an overview
While colorectal cancer screening is well-established in the UK, at present, it uses a ‘one-size fits-all’ approach – that is, individual risk is not considered when determining screening regimens (except for some specific conditions such as Lynch syndrome). Stratified screening offers the prospect of directing more intensive screening toward those at higher risk – with a corresponding reduction of screening intensity among lower-risk individuals. Two key opportunities for stratifying colorectal cancer screening are (1) making better use of an individual’s quantitative fecal hemoglobin result rather than the current approach of deeming tests to be positive over an arbitrary threshold and (2) gathering information on lifestyle, family history, genetics and other factors to establish risk of colorectal cancer – and using this information to tailor screening regimens. While there is encouraging evidence from modeling studies demonstrating reduced colonoscopy requirements and increased positive prediction of colorectal cancer when incorporating risk assessments within screening, we need ‘real world’ evidence on stratified screening to establish whether it is effective, improves screening outcomes and is acceptable to the public. We also need to know the impact these changes would have on existing screening programs, and how programs might adapt their organizational and IT processes.
- Open Access
- 14 February 2024
- Published by Wiley in European Journal of Cancer Care
- Vol. 2024, 1-13
Revisiting Cancer Diagnosis in Scotland: Further Insights from the Second Scottish National Cancer Diagnosis Audit
Objective. To characterise cancer diagnosis in Scottish primary care in 2018/19 and draw comparisons with diagnostic activity in 2014. Methods. A national audit of cancer diagnosis undertaken in Scottish general practices. Participating GPs collected diagnostic pathway data on patients diagnosed with cancer in 2018/19 from medical records. These data were supplemented by linkage to the Scottish Cancer Registry and previous audit data from 2014. Analyses explored and compared patient demographics, presentation, diagnostic routes, and intervals. Results. Seventy-three practices submitted data on 2,014 cases in 2014 and 90 practices submitted data on 2,318 cases in 2018/2019. Individual demographics and types of cancer were similar. There was a higher proportion of USC (urgent suspected cancer) referrals in 2019 than 2014 (42.9% vs 38.1%, ) but a similar proportion of emergency presentations (19.2% vs 20.4%). Primary care (median 4 (IQR 0–22) vs 5 (0–23)) and diagnostic intervals (27 (10–59) vs 30 (13–68)) were similar in both periods. Significantly fewer (24.5% vs 28.3, ) had a diagnostic interval >60 days in 2019 than 2014. Harder to diagnose cancers were more likely to present as emergencies and be subject to prolonged delays in both cohorts. Conclusions. The 2014 and 2018/19 cohorts were broadly similar. There is limited evidence that USC use had increased between 2014 and 2018/19. Harder to diagnose cancers are still most likely to present as emergencies and be subject to delays. Overall, it seems there were small improvements in cancer diagnosis prepandemic and a further audit could examine evidence for a postpandemic recovery.
- 14 February 2024
- Published by Wiley in European Journal of Cancer Care
- Vol. 2024, 1-13
Open AccessRevisiting Cancer Diagnosis in Scotland: Further Insights from the Second Scottish National Cancer Diagnosis Audit
Objective. To characterise cancer diagnosis in Scottish primary care in 2018/19 and draw comparisons with diagnostic activity in 2014. Methods. A national audit of cancer diagnosis undertaken in Scottish general practices. Participating GPs collected diagnostic pathway data on patients diagnosed with cancer in 2018/19 from medical records. These data were supplemented by linkage to the Scottish Cancer Registry and previous audit data from 2014. Analyses explored and compared patient demographics, presentation, diagnostic routes, and intervals. Results. Seventy-three practices submitted data on 2,014 cases in 2014 and 90 practices submitted data on 2,318 cases in 2018/2019. Individual demographics and types of cancer were similar. There was a higher proportion of USC (urgent suspected cancer) referrals in 2019 than 2014 (42.9% vs 38.1%, ) but a similar proportion of emergency presentations (19.2% vs 20.4%). Primary care (median 4 (IQR 0–22) vs 5 (0–23)) and diagnostic intervals (27 (10–59) vs 30 (13–68)) were similar in both periods. Significantly fewer (24.5% vs 28.3, ) had a diagnostic interval >60 days in 2019 than 2014. Harder to diagnose cancers were more likely to present as emergencies and be subject to prolonged delays in both cohorts. Conclusions. The 2014 and 2018/19 cohorts were broadly similar. There is limited evidence that USC use had increased between 2014 and 2018/19. Harder to diagnose cancers are still most likely to present as emergencies and be subject to delays. Overall, it seems there were small improvements in cancer diagnosis prepandemic and a further audit could examine evidence for a postpandemic recovery.
- 24 June 2022
- Published by SAGE Publications in InnovAiT: Education and Inspiration for General Practice
- Vol. 15 (9) , 525-531
Ovarian cancer in primary care
Ovarian cancer continues to be the leading cause of gynaecological cancer death in the UK. It has previously been described as the ‘silent killer’, as symptoms are typically absent or non-specific early in the disease leading to a later stage at diagnosis where fewer treatment options are available. Stage at presentation influences patient survival, and therefore, early detection within primary care is vital. Currently, there is no screening programme for ovarian cancer, and so diagnosis relies on investigation of symptomatic women presenting to healthcare professionals and an awareness of vague symptoms that could indicate ovarian cancer pathology. This article aims to provide an overview of ovarian cancer, including epidemiology, risk factors, signs and symptoms, and diagnosis within primary care. We will also briefly discuss current treatment strategies for ovarian cancer.
- 24 June 2022
- Published by SAGE Publications in InnovAiT: Education and Inspiration for General Practice
- Vol. 15 (9) , 525-531
Ovarian cancer in primary care
Ovarian cancer continues to be the leading cause of gynaecological cancer death in the UK. It has previously been described as the ‘silent killer’, as symptoms are typically absent or non-specific early in the disease leading to a later stage at diagnosis where fewer treatment options are available. Stage at presentation influences patient survival, and therefore, early detection within primary care is vital. Currently, there is no screening programme for ovarian cancer, and so diagnosis relies on investigation of symptomatic women presenting to healthcare professionals and an awareness of vague symptoms that could indicate ovarian cancer pathology. This article aims to provide an overview of ovarian cancer, including epidemiology, risk factors, signs and symptoms, and diagnosis within primary care. We will also briefly discuss current treatment strategies for ovarian cancer.
- Open Access
- 30 May 2022
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 32 (1) , 1-5
Lung cancer and Covid-19: lessons learnt from the pandemic and where do we go from here?
The Covid-19 pandemic has significantly disrupted all aspects of healthcare, and while the worst may be over, its broader impact on health services, such as cancer diagnosis and treatment, is likely to be profound. We examine, in this paper, how our response to Covid-19 impacted on the recognition, referral, and diagnosis of individuals with lung cancer in primary care. The overlapping nature of symptoms of Covid-19 and lung cancer posed a particular challenge, and lung cancer referrals have been slow to return to pre-pandemic levels. Strategies need to be implemented to ensure the impact of future variants does not derail the precarious recovery we are now witnessing in many countries—it is vital that the gains we have made in earlier diagnosis are not lost. The pandemic has underlined the importance of improving early diagnosis through public awareness raising of symptoms, rapid diagnostic facilities, reduced primary care diagnostic intervals and, potentially, the introduction of screening in high-risk groups.
- 30 May 2022
- Published by Springer Nature in npj Primary Care Respiratory Medicine
- Vol. 32 (1) , 1-5
Open AccessLung cancer and Covid-19: lessons learnt from the pandemic and where do we go from here?
The Covid-19 pandemic has significantly disrupted all aspects of healthcare, and while the worst may be over, its broader impact on health services, such as cancer diagnosis and treatment, is likely to be profound. We examine, in this paper, how our response to Covid-19 impacted on the recognition, referral, and diagnosis of individuals with lung cancer in primary care. The overlapping nature of symptoms of Covid-19 and lung cancer posed a particular challenge, and lung cancer referrals have been slow to return to pre-pandemic levels. Strategies need to be implemented to ensure the impact of future variants does not derail the precarious recovery we are now witnessing in many countries—it is vital that the gains we have made in earlier diagnosis are not lost. The pandemic has underlined the importance of improving early diagnosis through public awareness raising of symptoms, rapid diagnostic facilities, reduced primary care diagnostic intervals and, potentially, the introduction of screening in high-risk groups.
- 7 July 2006
- Published by Elsevier in Public Health
- Vol. 120 (8) , 752-759
Reducing variation in antibacterial prescribing rates for ‘cough/cold’ and sore throat between 1993 and 2001: Regional analyses using the general practice research database
- 7 July 2006
- Published by Elsevier in Public Health
- Vol. 120 (8) , 752-759
Reducing variation in antibacterial prescribing rates for ‘cough/cold’ and sore throat between 1993 and 2001: Regional analyses using the general practice research database